Difference between revisions of "Pimitespib (Jeselhy)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
*[[Gastrointestinal stromal tumor]] | *[[Gastrointestinal stromal tumor]] | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2022-06-20: A drug with a new active ingredient indicated for the treatment of [[gastrointestinal stromal tumor]] that has progressed after cancer chemotherapy. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' TAS-116 | *'''Code name:''' TAS-116 | ||
| Line 14: | Line 16: | ||
[[Category:Hsp90 inhibitors]] | [[Category:Hsp90 inhibitors]] | ||
[[Category:Gastrointestinal stromal tumor medications]] | [[Category:Gastrointestinal stromal tumor medications]] | ||
| − | [[Category:PMDA approved | + | [[Category:PMDA approved in 2022]] |
Latest revision as of 14:36, 6 June 2023
Mechanism of action
From the NCI Drug Dictionary: A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, Hsp90alpha/beta inhibitor TAS-116 specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta.
Diseases for which it is used
History of changes in PMDA indication
- 2022-06-20: A drug with a new active ingredient indicated for the treatment of gastrointestinal stromal tumor that has progressed after cancer chemotherapy.
Also known as
- Code name: TAS-116
- Brand name: Jeselhy